Literature DB >> 27473453

Clinical and immunologic features of recurrent herpes zoster (HZ).

Yuki Nakamura1, Fumi Miyagawa1, Aiko Okazaki1, Yoshinobu Okuno2, Yasuko Mori3, Hiroyasu Iso4, Koichi Yamanishi5, Hideo Asada6.   

Abstract

BACKGROUND: Recurrent herpes zoster (HZ) is thought to be rare, but there have been few large-scale studies of recurrent HZ.
OBJECTIVE: We conducted a large-scale prospective cohort study to characterize recurrent HZ.
METHODS: We examined 12,522 participants aged 50 years or older in Shozu County and followed them up for 3 years. We compared the incidence of HZ and postherpetic neuralgia, severity of skin lesions and acute pain, cell-mediated immunity, and varicella-zoster virus-specific antibody titer between primary and recurrent HZ.
RESULTS: A total of 401 participants developed HZ: 341 with primary HZ and 60 with recurrent HZ. Skin lesions and acute pain were significantly milder and the incidence of postherpetic neuralgia was lower in patients aged 50 to 79 years with recurrent HZ than in those with primary HZ. Varicella-zoster virus skin test induced a stronger reaction in patients aged 50 to 79 years with recurrent HZ than in those with primary HZ. LIMITATIONS: Information on previous HZ episodes was self-reported by participants, so it could not be confirmed that they actually had a history of HZ.
CONCLUSION: Recurrent HZ was associated with milder clinical symptoms than primary HZ, probably because of stronger varicella-zoster virus-specific cell-mediated immunity in the patients with recurrence.
Copyright © 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cell-mediated immunity; humoral immunity; large-scale community-based prospective cohort study; primary herpes zoster; recurrent herpes zoster; varicella-zoster virus

Mesh:

Substances:

Year:  2016        PMID: 27473453     DOI: 10.1016/j.jaad.2016.05.037

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  4 in total

1.  Burden of Herpes Zoster in Adult Patients with Underlying Conditions: Analysis of German Claims Data, 2007-2018.

Authors:  Manuel Batram; Julian Witte; Magdalena Schwarz; Johannes Hain; Bernhard Ultsch; Maren Steinmann; Amit Bhavsar; Peter Wutzler; Carl-Peter Criée; Christiane Hermann; Klaus Wahle; Martin Füchtenbusch; Wolfgang Greiner
Journal:  Dermatol Ther (Heidelb)       Date:  2021-05-06

2.  Recurrent herpes zoster in a rheumatoid arthritis patient treated with tofacitinib: A case report and review of the literature.

Authors:  Qing-Xia Lin; Hui-Juan Meng; Yun-Yan Pang; Yan Qu
Journal:  World J Clin Cases       Date:  2022-08-26       Impact factor: 1.534

3.  The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults ≥50 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence.

Authors:  Hung Fu Tseng; Katia Bruxvoort; Bradley Ackerson; Yi Luo; Hilary Tanenbaum; Yun Tian; Chengyi Zheng; Bianca Cheung; Brandon J Patterson; Desiree Van Oorschot; Lina S Sy
Journal:  J Infect Dis       Date:  2020-08-04       Impact factor: 5.226

4.  Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment.

Authors:  Kevin L Winthrop; Jeffrey R Curtis; Kunihiro Yamaoka; Eun Bong Lee; Tomohiro Hirose; Jose L Rivas; Kenneth Kwok; Gerd R Burmester
Journal:  Rheumatol Ther       Date:  2021-12-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.